Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline

BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)‐4/IL‐13, key drivers of type 2 inflammation. In phase 2b (NCT01854047) and phase 3 LIBERTY ASTHMA QUEST (NCT02414854), add‐on dupilumab 200/300 mg every 2 weeks (q2w) reduced severe exacerbations, improved prebronchodila...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Allergy
Main Authors: Bourdin, Arnaud, Papi, Alberto A., Corren, Jonathan, Virchow, J. Christian, Rice, Megan S., Deniz, Yamo, Djandji, Michel, Rowe, Paul, Pavord, Ian D.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
ORIGINAL ARTICLES
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7820970/
https://ncbi.nlm.nih.gov/pubmed/33010038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.14611
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados